Selinexor

Generic Name
Selinexor
Brand Names
Xpovio 100 Mg Once Weekly Carton, Nexpovio
Drug Type
Small Molecule
Chemical Formula
C17H11F6N7O
CAS Number
1393477-72-9
Unique Ingredient Identifier
31TZ62FO8F
Background

Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...

Indication

Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...

Associated Conditions
Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
Associated Therapies
-
Clinical Trials
Related News

Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients

First Posted Date
2015-02-20
Last Posted Date
2023-01-20
Lead Sponsor
Karyopharm Therapeutics Inc
Registration Number
NCT02367690
Locations
🇳🇿

South Pacific Clinical Trials, Auckland, New Zealand

Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer

First Posted Date
2015-01-30
Last Posted Date
2016-05-16
Lead Sponsor
Erin Bertino
Target Recruit Count
1
Registration Number
NCT02351505
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Selinexor and Backbone Treatments of Multiple Myeloma Patients

First Posted Date
2015-01-21
Last Posted Date
2024-05-07
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
300
Registration Number
NCT02343042
Locations
🇺🇸

Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States

🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

and more 21 locations

Selinexor Treatment of Refractory Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Selinexor
Drug: Dexamethasone
First Posted Date
2015-01-13
Last Posted Date
2023-01-26
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
202
Registration Number
NCT02336815
Locations
🇺🇸

Jonnsson Comprehensive Cancer Center / University of Los Angeles, Los Angeles, California, United States

🇺🇸

Hackensack University Medical Center / John Therurer Cancer Center, Hackensack, New Jersey, United States

🇺🇸

Sylvester, University of Miami, Miami, Florida, United States

and more 58 locations

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

First Posted Date
2014-12-24
Last Posted Date
2024-11-19
Lead Sponsor
Children's Oncology Group
Target Recruit Count
59
Registration Number
NCT02323880
Locations
🇺🇸

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States

🇺🇸

Seattle Children's Hospital, Seattle, Washington, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 20 locations

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

First Posted Date
2014-12-11
Last Posted Date
2023-01-26
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
16
Registration Number
NCT02314247
Locations
🇦🇺

Concord Repatriation General Hospital (CRGH), Concord, New South Wales, Australia

🇦🇺

Westmead Hospital, Westmead, New South Wales, Australia

🇦🇺

Cabrini Hospital, Malvern, Victoria, Australia

and more 2 locations

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

First Posted Date
2014-11-27
Last Posted Date
2022-05-02
Lead Sponsor
Jennifer Woyach
Target Recruit Count
34
Registration Number
NCT02303392
Locations
🇺🇸

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

First Posted Date
2014-11-24
Last Posted Date
2023-06-15
Lead Sponsor
Alice Mims
Target Recruit Count
23
Registration Number
NCT02299518
Locations
🇺🇸

The State Ohio University Comprehensive Cancer Center, Columbus, Ohio, United States

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

First Posted Date
2014-11-05
Last Posted Date
2016-01-15
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
3
Registration Number
NCT02283359
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

First Posted Date
2014-10-21
Last Posted Date
2021-04-23
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
23
Registration Number
NCT02269293
Locations
🇺🇸

Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Memorial Sloan Kettering Westchester, Harrison, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy